Clinical Trial News and Research

RSS

SuperGen second quarter net income decreases to $903,000

SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.

3 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

BioClinica second quarter service revenues increase 8.7% to $16.9 million

BioClinica Inc., a global provider of clinical trial management solutions, today announced its financial results for the second quarter and six months ended June 30, 2011.

From Clario 3 Aug 2011

Combination molecules with BRAF inhibitors may help overcome drug resistance in melanoma patients

About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.

3 Aug 2011

EAST clinical trial to assess early comprehensive rhythm control therapy for AF

The first patient has been enrolled, in Hamburg, Germany, for the largest pan-European study to determine whether an early comprehensive rhythm control strategy for the treatment of atrial fibrillation (AF) will benefit patients.

3 Aug 2011

Positive results from combination drug trial for late-stage ovarian cancer

An experimental two-drug combination for treating late-stage ovarian cancer continues to produce strong results, leading its Indiana University researchers to actively pursue the next step, conducting a larger clinical trial to test the therapy and to see how it compares with existing treatments for ovarian cancer.

3 Aug 2011

Memantine drug could boost cognitive function in people with Down syndrome

A University of Colorado School of Medicine scientist is completing a major clinical trial on a drug that could boost cognitive function in those with Down syndrome, significantly improving their quality of life and representing a potential milestone in research on this genetic condition.

3 Aug 2011

OUP, PIDS partner to publish Journal of the Pediatric Infectious Diseases Society

Oxford University Press (OUP) will partner with the Pediatric Infectious Diseases Society (PIDS) to publish the Journal of the Pediatric Infectious Diseases Society.

3 Aug 2011

Tornier announces two milestone events for Simpliciti stemless shoulder system

Tornier N.V., a leading global medical device company focused on serving extremities specialists who treat orthopaedic conditions of the shoulder, elbow, wrist, hand, ankle and foot, today announced two milestone events for the Company's new SimplicitiTM stemless shoulder joint replacement system.

3 Aug 2011

Bear bile compound may help treat heart attack: Study

The compound, ursodeoxycholic acid (UDCA), is already used to lower cholesterol and help dissolve gallstones, and it's a key ingredient in many traditional Chinese medicines, which use bear bile. According to the latest research from Imperial College London it might also be able to treat abnormal heart rhythm, or arrhythmia, in fetuses and heart attack victims.

3 Aug 2011

Novel therapy reduces elevated blood levels of toxic protein in women with preeclampsia

A novel therapy that reduces elevated blood levels of a potentially toxic protein in women with preeclampsia, a dangerous complication of pregnancy, may someday address the therapeutic dilemma posed by the condition - balancing life-threatening risks to the mother with the dangers that early delivery poses to an immature fetus.

3 Aug 2011

FDA grants IDE approval for Apnex HGNS System to treat obstructive sleep apnea

Apnex Medical, Inc., received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a clinical study to evaluate the safety and effectiveness of its Hypoglossal Nerve Stimulation System to treat obstructive sleep apnea.

3 Aug 2011

Exact Sciences second quarter total revenues decreases to $1.0 million

Exact Sciences Corp. today announced its financial results for the quarter ended June 30, 2011.

2 Aug 2011

Enrollment commences in St. Jude Medical's atrial fibrillation stroke prevention trial

St. Jude Medical, Inc., a global medical device company, today announced that the first patient was enrolled in the EAST (Early comprehensive Atrial fibrillation Stroke prevention Trial) clinical trial.

2 Aug 2011

ARIAD reports $47.8 million net loss for second quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010 and provided an update on corporate developments.

2 Aug 2011

Rigel reports net loss of $21.5 million for second quarter 2011

Rigel Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2011.

2 Aug 2011

FDA accepts MAP Pharmaceuticals' LEVADEX NDA for filing

MAP Pharmaceuticals, Inc. today announced that its New Drug Application (NDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA), with a goal date of March 26, 2012 under the Prescription Drug User Fee Act (PDUFA).

2 Aug 2011

NYU Langone receives NHLBI grant for comparative effectiveness ISCHEMIA Trial

NYU Langone Medical Center announced it has received an $84 million grant from the National Heart, Lung, and Blood Institute (NHLBI), of the National Institutes of Health (NIH), to study the comparative effectiveness of two initial management strategies for patients with coronary artery disease.

2 Aug 2011

AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation

AstraZeneca today announced that study centers across the U.S. are recruiting patients for a clinical study to examine whether an investigational drug is safe and effective in treating opioid-induced constipation.

2 Aug 2011

Positive results from Jennerex JX-594 proof-of-concept trial on metastatic melanoma

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that positive results from a proof-of-concept clinical trial using JX-594 to treat patients with metastatic melanoma were published in the peer-reviewed journal Molecular Therapy.

2 Aug 2011